Barclays PLC Pacira Bio Sciences, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Pacira Bio Sciences, Inc. stock. As of the latest transaction made, Barclays PLC holds 405,477 shares of PCRX stock, worth $7.7 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

405,477

Previous 405,477 -0.0%

Holding current value

$7.7 Million

Previous $6.1 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	SELL	$11.7 - $28.46 $184,602 - $449,041	-15,778 Reduced 3.75%	405,477 $6.1 Million
Q2 2024 Aug 14, 2024	BUY	$25.5 - $31.51 $9.22 Million - $11.4 Million	361,479 Added 604.72%	421,255 $12.1 Million
Q1 2024 May 15, 2024	SELL	$27.7 - $35.48 $700,062 - $896,686	-25,273 Reduced 29.72%	59,776 $1.75 Million
Q4 2023 Feb 15, 2024	BUY	$26.32 - $34.31 $1.36 Million - $1.77 Million	51,645 Added 154.61%	85,049 $2.87 Million
Q3 2023 Nov 07, 2023	BUY	$30.68 - $40.09 $45,805 - $59,854	1,493 Added 4.68%	33,404 $1.03 Million
Q2 2023 Aug 03, 2023	SELL	$36.12 - $47.5 $78,669 - $103,455	-2,178 Reduced 6.39%	31,911 $1.28 Million
Q1 2023 May 04, 2023	BUY	$35.53 - $43.38 $237,020 - $289,387	6,671 Added 24.33%	34,089 $1.39 Million
Q4 2022 Feb 13, 2023	BUY	$38.19 - $57.45 $383,160 - $576,395	10,033 Added 57.71%	27,418 $1.06 Million
Q3 2022 Nov 03, 2022	SELL	$51.24 - $58.89 $282,844 - $325,072	-5,520 Reduced 24.1%	17,385 $924,000
Q2 2022 Aug 12, 2022	SELL	$51.49 - $81.64 $982,841 - $1.56 Million	-19,088 Reduced 45.46%	22,905 $1.34 Million
Q1 2022 May 16, 2022	SELL	$60.03 - $76.49 $1.79 Million - $2.28 Million	-29,759 Reduced 41.47%	41,993 $3.21 Million
Q4 2021 Feb 14, 2022	BUY	$47.97 - $62.21 $547,577 - $710,127	11,415 Added 18.92%	71,752 $4.32 Million
Q3 2021 Nov 09, 2021	BUY	$54.64 - $61.3 $1.66 Million - $1.86 Million	30,373 Added 101.36%	60,337 $3.38 Million
Q2 2021 Aug 13, 2021	SELL	$59.18 - $69.99 $1.53 Million - $1.81 Million	-25,797 Reduced 46.26%	29,964 $1.82 Million
Q1 2021 May 13, 2021	BUY	$59.31 - $78.82 $58,894 - $78,268	993 Added 1.81%	55,761 $3.91 Million
Q4 2020 Feb 11, 2021	BUY	$50.47 - $66.26 $144,445 - $189,636	2,862 Added 5.51%	54,768 $3.28 Million
Q3 2020 Nov 12, 2020	BUY	$51.97 - $63.0 $661,110 - $801,423	12,721 Added 32.46%	51,906 $3.12 Million
Q2 2020 Aug 12, 2020	SELL	$30.8 - $52.47 $13,582 - $23,139	-441 Reduced 1.11%	39,185 $2.06 Million
Q1 2020 May 13, 2020	SELL	$28.4 - $50.7 $695,714 - $1.24 Million	-24,497 Reduced 38.2%	39,626 $1.33 Million
Q4 2019 Feb 10, 2020	BUY	$36.31 - $46.83 $606,268 - $781,920	16,697 Added 35.21%	64,123 $2.9 Million
Q3 2019 Nov 14, 2019	BUY	$35.66 - $44.99 $243,664 - $307,416	6,833 Added 16.83%	47,426 $1.81 Million
Q2 2019 Aug 14, 2019	SELL	$36.57 - $47.97 $715,016 - $937,909	-19,552 Reduced 32.51%	40,593 $1.77 Million
Q1 2019 May 15, 2019	BUY	$36.47 - $42.17 $1.94 Million - $2.24 Million	53,166 Added 761.8%	60,145 $2.29 Million
Q4 2018 Feb 14, 2019	SELL	$41.31 - $52.16 $601,432 - $759,397	-14,559 Reduced 67.6%	6,979 $300,000
Q3 2018 Nov 14, 2018	BUY	$32.85 - $52.0 $447,646 - $708,604	13,627 Added 172.25%	21,538 $1.06 Million
Q2 2018 Aug 14, 2018	SELL	$27.5 - $39.8 $67,292 - $97,390	-2,447 Reduced 23.62%	7,911 $254,000
Q1 2018 May 15, 2018	BUY	$29.98 - $46.35 $839 - $1,297	28 Added 0.27%	10,358 $323,000
Q4 2017 Feb 14, 2018	SELL	$31.85 - $46.95 $241,900 - $356,585	-7,595 Reduced 42.37%	10,330 $473,000
Q3 2017 Nov 14, 2017	BUY	$35.7 - $39.5 $639,922 - $708,037	17,925	17,925 $673,000

Others Institutions Holding PCRX

# of Institutions

263

Shares Held

50.4M

Call Options Held

429K

Put Options Held

391K

View Full List

About Pacira BioSciences, Inc.

Ticker PCRX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 45,824,200
Market Cap $870M
Description
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid ...

More about PCRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account